Hitting a 95-mph fastball is said to be the hardest thing to do in sports, but a study published in PLoS One shows that a key nutrient may make that fastball seem a little slower, according to a news release from ZeaVision.1 The study by the University…
Category: Refractive
GrayBug Raises $1.74 Million in Series A2 Financing
GrayBug, a privately held pharmaceutical company developing drug-delivery therapies and sustained-release compounds for the treatment of eye diseases, announced the closing of a $1.74-million Series A2 financing round led by new investor Hatteras Ventu…
Nightstar Receives Orphan Drug Designation for Gene Therapy to Treat Choroideremia
Nightstar has received FDA and European Medicines Agency Orphan Drug Designation for its gene therapy to treat choroideremia, an X-linked recessive disorder that leads to progressive blindness, according to a company news release.
Orphan Drug Design…
Imprimis and Cleveland Eye Clinic Announce Results of Lessdrops Formulation
Imprimis Pharmaceuticals and Cleveland Eye Clinic announced positive results of an investigator-initiated evaluation validating the use of Imprimis’ proprietary combination topical formulations for patients post-LASIK surgery, according to a company news release.
The evaluation of Imprimis’ proprietary Tri-Moxi (tr…
Valeant To Acquire Salix Pharmaceuticals in a Deal Worth About $14.5 Billion
Valeant To Acquire Salix Pharmaceuticals in a Deal Worth About $14.5 Billion
Valeant Pharmaceuticals International and Salix Pharmaceuticals announced that they have entered into a definitive agreement under which Valeant will acquire all of the…
FDA Advisory Panel Recommends Approval of Avedro’s CXL Platform
A joint FDA advisory panel recommended approval of Avedro’s combined riboflavin ophthalmic solutions and ultraviolet (UV) light irradiation for corneal collagen cross-linking. The recommendation is the last step before the FDA renders a decision on March 29.
The FDA’s Dermatologic and Ophthalmic Drugs Advisory…
Protocol T Comparing Three DME Agents Released
Protocol T Comparing Three DME Agents Released
A major government-sponsored study shows that intravitreous aflibercept (Eylea; Regeneron), bevacizumab (Avastin; Genentech), and ranibizumab (Lucentis; Genentech) were effective and safe treatments f…
Stem Cells From Wisdom Teeth Can Be Transformed Into Corneal Cells
Stem Cells From Wisdom Teeth Can Be Transformed Into Corneal Cells
Stem cells from the dental pulp of wisdom teeth can be turned into cells of the eye’s cornea and could one day be used to repair corneal scarring due to infection or injury, according to researchers at the University of Pittsburgh School of Medicine….
Erratum
Erratum
CRST regrets the misspelling of Verus (Mile High Ophthalmics) in the sidebar A Silicone Ring for Capsulotomy Creation by Robert J. Cionni, MD, that appeared in our November/December 2014 edition.
…
Actavis Announces Intention to Adopt “Allergan” Corporate Name
Actavis Announces Intention to Adopt “Allergan” Corporate Name
Actavis announced that following the completion of the acquisition of Allergan, it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio. It will retain the Actavis name for select geographic regio…
Combined ECP and Phaco Reduced IOP in Eyes With Mild to Moderate Glaucoma
Combined endocyclophotocoagulation (ECP) and
phacoemulsification significantly reduced IOP in
patients with mild to moderate glaucoma, according
to data presented by Michael J. Siegel, MD, and colleagues
at the Association for Research in Vision …
Ista Pleads Guilty to Felony Charges
Ista Pharmaceuticals, Inc., pled guilty to two felony
charges by the United States Justice Department related
to the marketing, distribution, and sale of its ophthalmic
drug Xibrom. As part of the settlement, Ista agreed
to pay $33.5 million in civil a…
Nicox to Promote Immco Diagnostics’ Test for the Early Detection of Sjögren Syndrome
Nicox SA announced that it has entered into an
exclusive agreement with Immco Diagnostics, Inc., a provider
of autoimmune diagnostic products and services,
to promote a proprietary laboratory test for the early
detection and diagnosis of Sjögren syndrome, according
to a Nicox news release.
Under the terms of the ag…
Intracameral Illumination Effective During Combined Cataract Virectomy Surgery in Eyes With Poor Red Reflex
Surgeon-controlled intracameral illumination can be
used for challenging cataract surgery combined with
23-gauge vitrectomy in eyes with a poor red reflex,
according to a study in the Journal of Cataract and
Refractive Surgery.sup1/sup
The interventio…
Full Range of Vision Achieved With the Kamra Corneal Inlay 5 Years Postoperatively
Patients with the Kamra inlay (AcuFocus, Inc.; not
approved in the United States) achieved J2 uncorrected
near visual acuity and 20/25 for both uncorrected
intermediate and distance visual acuities 5 years postoperatively,
according to a company news r…
New Layer of the Cornea Discovered
Scientists at The University of Nottingham, United
Kingdom, have discovered a previously undetected
layer in the cornea that could help surgeons to dramatically
improve outcomes for patients undergoing corneal
grafts and transplants, according to a new…
Perrigo Acquires Fera Pharmaceuticals’ Ophthalmic Portfolio
Perrigo Company has signed a definitive agreement
to acquire the ophthalmic sterile ointment and solution
product portfolio from Fera Pharmaceuticals, LLC, and
its affiliates, according to a Perrigo news release.
Terms of the transaction include an up…
Granuloma-Like Opacity Characteristic of Cataracts Caused by Ocular Toxocariasis
Cataracts caused by ocular toxocariasis have a
granuloma-like opacity primarily in the posterior subcapsular
level, according to a study in the Journal of
Cataract and Refractive Surgery.sup1/sup
The investigators based the clinical diagnosis of ocula…
Catalys Precision Laser System to Be Used in French Clinical Trial
OptiMedica Corporation announced that it has
been awarded a tender for five Catalys Precision Laser
Systems for use in a French multicenter randomized
clinical study.
The study, which is sponsored by Centre Hospitalier
Universitaire de Bordeaux, Franc…
InSite Vision Starts Patient Enrollment in Confirmatory Phase 3 Clinical Trial of BromSite
Enrollment has begun in the confirmatory phase 3
clinical trial of BromSite (ISV-303; InSite Vision Inc.) for
the reduction of inflammation and pain after cataract
surgery.
ISV-303 combines a low dose (0.075%) of the nonsteroidal
antiinflammatory drug bromfenac with
InSite’s DuraSite drug delivery technology. This…